Alnylam Pharmaceuticals (ALNY) Capital Expenditures Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Capital Expenditures Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,015.37 Bn | 1,015.37 Bn | - | - |
| 4 | BeOne Medicines | 471.39 Bn | 466.59 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.52 Bn | 115.28 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.33 Bn | 61.58 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 16.27% |
| 10 | Revolution Medicines | 37.34 Bn | 37.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.27% |
| Dec 31, 2025 | -9.35% |
| Sep 30, 2025 | 21.05% |
| Jun 30, 2025 | -3.80% |
| Mar 31, 2025 | -20.51% |
| Dec 31, 2024 | 30.50% |
| Sep 30, 2024 | -2.55% |
| Jun 30, 2024 | -27.15% |
| Mar 31, 2024 | -32.50% |
| Dec 31, 2023 | -8.04% |
| Sep 30, 2023 | 11.24% |
| Jun 30, 2023 | -18.73% |
| Mar 31, 2023 | 28.03% |
| Dec 31, 2022 | -18.39% |
| Sep 30, 2022 | 15.72% |
| Jun 30, 2022 | -32.52% |
| Mar 31, 2022 | 11.07% |
| Dec 31, 2021 | 10.01% |
| Sep 30, 2021 | -26.67% |
| Jun 30, 2021 | 18.04% |